WallStSmart

AbbVie Inc (ABBV)vsPrestige Brand Holdings Inc (PBH)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

AbbVie Inc generates 5442% more annual revenue ($61.16B vs $1.10B). PBH leads profitability with a 16.9% profit margin vs 6.9%. ABBV appears more attractively valued with a PEG of 0.48. ABBV earns a higher WallStSmart Score of 63/100 (C+).

ABBV

Buy

63

out of 100

Grade: C+

Growth: 4.0Profit: 8.0Value: 4.7Quality: 5.0
Piotroski: 5/9Altman Z: 0.40

PBH

Buy

57

out of 100

Grade: C

Growth: 2.7Profit: 7.5Value: 5.3Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ABBVSignificantly Overvalued (-29.3%)

Margin of Safety

-29.3%

Fair Value

$163.42

Current Price

$211.32

$47.90 premium

UndervaluedFair: $163.42Overvalued
PBHOvervalued (-13.3%)

Margin of Safety

-13.3%

Fair Value

$58.22

Current Price

$56.02

$2.20 premium

UndervaluedFair: $58.22Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ABBV6 strengths · Avg: 9.7/10
Market CapQuality
$360.63B10/10

Mega-cap, among the largest globally

PEG RatioValuation
0.4810/10

Growing faster than its price suggests

Return on EquityProfitability
62.3%10/10

Every $100 of equity generates 62 in profit

Operating MarginProfitability
34.1%10/10

Strong operational efficiency at 34.1%

Debt/EquityHealth
-21.0610/10

Conservative balance sheet, low leverage

Free Cash FlowQuality
$4.89B8/10

Generating 4.9B in free cash flow

PBH3 strengths · Avg: 8.7/10
Price/BookValuation
1.4x10/10

Reasonable price relative to book value

P/E RatioValuation
14.8x8/10

Attractively priced relative to earnings

Operating MarginProfitability
29.1%8/10

Strong operational efficiency at 29.1%

Areas to Watch

ABBV4 concerns · Avg: 2.3/10
Profit MarginProfitability
6.9%3/10

6.9% margin — thin

P/E RatioValuation
100.0x2/10

Premium valuation, high expectations priced in

EPS GrowthGrowth
-88.7%2/10

Earnings declined 88.7%

Altman Z-ScoreHealth
0.402/10

Distress zone — elevated risk

PBH3 concerns · Avg: 2.7/10
PEG RatioValuation
1.904/10

Expensive relative to growth rate

Revenue GrowthGrowth
-2.4%2/10

Revenue declined 2.4%

EPS GrowthGrowth
-20.5%2/10

Earnings declined 20.5%

Comparative Analysis Report

WallStSmart Research

Bull Case : ABBV

The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. PEG of 0.48 suggests the stock is reasonably priced for its growth.

Bull Case : PBH

The strongest argument for PBH centers on Price/Book, P/E Ratio, Operating Margin. Profitability is solid with margins at 16.9% and operating margin at 29.1%.

Bear Case : ABBV

The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 100.0x leaves little room for execution misses.

Bear Case : PBH

The primary concerns for PBH are PEG Ratio, Revenue Growth, EPS Growth.

Key Dynamics to Monitor

ABBV profiles as a value stock while PBH is a declining play — different risk/reward profiles.

PBH carries more volatility with a beta of 0.47 — expect wider price swings.

ABBV is growing revenue faster at 10.0% — sustainability is the question.

ABBV generates stronger free cash flow (4.9B), providing more financial flexibility.

Bottom Line

ABBV scores higher overall (63/100 vs 57/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

AbbVie Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.

Prestige Brand Holdings Inc

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Prestige Consumer Healthcare Inc., develops, manufactures, markets, distributes and sells over-the-counter (OTC) healthcare products in the United States and internationally. The company is headquartered in Tarrytown, New York.

Want to dig deeper into these stocks?